Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Br J Psychiatry
; 174: 23-30, 1999 Jan.
Article
em En
| MEDLINE
| ID: mdl-10211147
ABSTRACT
BACKGROUND:
Tardive dyskinesia is important in the side-effect profile of antipsychotic medication.AIMS:
The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years.METHODS:
Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD), it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated.RESULTS:
The relative risk of tardive dyskinesia for the overall follow up period for haloperidol (n = 522) v. olanzapine (n = 1192) was 2.66 (95% CI = 1.50-4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n = 513) and 7.45% with haloperidol (n = 114). The relative risk throughout this follow-up period was 11.37 (95% CI = 2.21-58.60).CONCLUSION:
Our results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esquizofrenia
/
Antipsicóticos
/
Pirenzepina
/
Discinesia Induzida por Medicamentos
/
Haloperidol
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Incidence_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Br J Psychiatry
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Estados Unidos